Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Jun 4, 2019- Targeting CXCR4 May Impact Aggressive Metastatic Behavior of Cancer Cells, Which May be Related to a Poor PrognosisEisai today announced additional data from an ongoing Phase 1 trial exploring the investigational combination of eribulin and balixafortide, a CXCR4 antagonist, in patients with HER2-negative...
-
May 16, 2019- Data highlight continued progress on clinical trials for the LENVIMA plus KEYTRUDA combination across multiple tumor types, including endometrial carcinoma (EC), for which the combination was granted U.S. FDA Breakthrough Therapy Designation in July 2018
Eisai today announced the presentation of new data and analyses in one oral presentation, 11 posters at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4 in...
-
Mar 29, 2019- Results from Independent Imaging Review of patients with hepatocellular carcinoma receiving lenvatinib+pembrolizumab in KEYNOTE-524 / Study 116 after five additional months of follow-up will be presented
Eisai announces today that one mini-symposium and 15 poster presentations from its oncology pipeline will be highlighted at the American Association for Cancer Research (AACR) 110th Annual Meeting...
-
Mar 6, 2019
Eisai announced today that new data from a real world observational study of the use of eribulin mesylate injection (marketed as HALAVEN®) following cyclin-dependent kinase (CDK) 4/6 inhibitor in...
-
Feb 11, 2019
Presenting sponsor Eisai Inc. and METAvivor announce today that they have joined forces with AnaOno Intimates and Project #Cancerland to bring to life the #ThisIsMBC Elements campaign through...